Loading…
A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo
In this study, a Cu 2+ chelate of the novel thiosemicarbazone NSC 689534 was evaluated for in vitro and in vivo anti-cancer activity. Results demonstrated that NSC 689534 activity (low micromolar range) was enhanced four- to fivefold by copper chelation and completely attenuated by iron. Importantly...
Saved in:
Published in: | Free radical biology & medicine 2011-01, Vol.50 (1), p.110-121 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | In this study, a Cu
2+ chelate of the novel thiosemicarbazone NSC 689534 was evaluated for in vitro and in vivo anti-cancer activity. Results demonstrated that NSC 689534 activity (low micromolar range) was enhanced four- to fivefold by copper chelation and completely attenuated by iron. Importantly, once formed, the NSC 689534/Cu
2+ complex retained activity in the presence of additional iron or iron-containing biomolecules. NSC 689534/Cu
2+ mediated its effects primarily through the induction of ROS, with depletion of cellular glutathione and protein thiols. Pretreatment of cells with the antioxidant
N-acetyl-l-cysteine impaired activity, whereas NSC 689534/Cu
2+ effectively synergized with the glutathione biosynthesis inhibitor buthionine sulfoximine. Microarray analysis of NSC 689534/Cu
2+-treated cells highlighted activation of pathways involved in oxidative and ER stress/UPR, autophagy, and metal metabolism. Further scrutiny of the role of ER stress and autophagy indicated that NSC 689534/Cu
2+-induced cell death was ER-stress dependent and autophagy independent. Last, NSC 689534/Cu
2+ was shown to have activity in an HL60 xenograft model. These data suggest that NSC 689534/Cu
2+ is a potent oxidative stress inducer worthy of further preclinical investigation. |
---|---|
ISSN: | 0891-5849 1873-4596 1873-4596 |
DOI: | 10.1016/j.freeradbiomed.2010.10.696 |